Canada: Food and Drugs Law

Le CEPMB a publié son édition de septembre 2026 de la Nouvelle, annonçant des nominations clés et détaillant le premier engagement pris sous les nouvelles Lignes directrices concernant IMCIVREE de Rhythm Pharmaceuticals.

Santé Canada a publié plusieurs lignes directrices révisées et nouvelles politiques en septembre 2026, touchant les exigences de notification des mesures réglementaires étrangères, les rapports de synthèse pour les produits de santé, et l'application de la loi. Ces mises à jour clarifient les obligations des parties réglementées et introduisent un projet pilote pour les examens conjoints du Consortium Access.

Le 21 septembre 2026 a marqué le neuvième anniversaire des modifications importantes apportées au Règlement sur les médicaments brevetés (avis de conformité). Cet article examine les tendances des litiges pharmaceutiques au Canada, notamment le nombre record de faibles procédures engagées et l'absence de décisions sur le fond rendues par la Cour fédérale. L'analyse couvre également les actions en cours, les procédures sommaires et les dem

The British Columbia Court of Appeal has left open the possibility that pharmaceutical manufacturers may owe a duty of care to develop safer alternatives to their existing products, even when those products are properly approved and labeled. This decision in Gilead Sciences, Inc. v. I.F. contrasts sharply with a recent California Supreme Court ruling that rejected such a "duty to innovate," potentially setting Canada on a divergent path in product liability law.

Health Canada's recent enforcement action against unauthorized injectable peptides signals a regulatory shift that wellness companies cannot afford to ignore. While peptides dominate influencer marketing and online wellness spaces, their legal status in Canada depends on factors far more complex than social media trends suggest. Understanding how route of administration, therapeutic claims, and market authorization intersect is now critical for compliance.

The Government of Alberta has reportedly become the first jurisdiction in Canada to use artificial intelligence (“AI”) in the initial drafting of the Alberta Whisky Act (the “Whisky Act”). The Whisky Act, which came into effect on May 21, 2026, establishes new standards and definitions for what qualifies as “Alberta Whisky”, including requirements relating to production standards, ingredients, and processes. According to the province, AI was used as part of the drafting process, with government officials and legislative counsel retaining responsibility for review, revision, and all levels of approval.

Canada's whisky and spirits market presents significant opportunities for international producers, but success requires careful navigation of a dual regulatory framework. Federal laws govern production standards, excise duties, and labelling requirements, while each province maintains its own liquor authority controlling distribution, sales, marketing, and pricing within its borders. Understanding these overlapping jurisdictions and tailoring market entry strategies to provincial variations is essential for

Health Canada has launched a public consultation on a proposed mandatory food packaging framework that would require notifications for all food contact materials sold in Canada. The initiative aims to enhance oversight of chemical exposures through a new knowledgebase system that cross-references submitted information against evaluated materials, with a five-year phase-in period anticipated following regulatory development.

Le 29 juillet 2026, Santé Canada a annoncé avoir obtenu une injonction permanente contre une entreprise basée au Québec relativement à la vente de peptides injectables non autorisés au Canada.